Search clinical trials for: Aromatase Inhibitors

Total 64079 results

University of Texas Southwestern Medical Center
Cancer Prevention Research Institute of Texas

Active, not recruiting

Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

Breast Cancer Female

United States
MedSIR
Eli Lilly and Company

Active, not recruiting

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL (ABIGAIL)

Breast Cancer Metastatic

Italy, Spain, Portugal
Case Comprehensive Cancer Center

Suspended

Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer

HR-positive Breast Cancer

United States
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

United States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Breast Cancer

China
Veru Inc.

Terminated

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer (VERU-024)

Metastatic Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (BioItaLEE)

Breast Cancer

Italy
Dana-Farber Cancer Institute
Pfizer

Completed

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Breast Cancer

United States
UNICANCER

Completed

Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation (LIBER)

Breast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | brca1 Mutation Carrier | brca2 Mutation Carrier

France
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | HER2-positive Breast Cancer | Advanced Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
Latin American Cooperative Oncology Group
Pfizer

Completed

Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer (LACOG1018)

Ovarian Cancer

Brazil
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

HER2/Neu Negative | Stage IV Breast Cancer AJCC v6 and v7 | Estrogen Receptor and/or Progesterone Receptor Positive

United States
Dubai Fertility Center

Withdrawn

Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients.

Miscarriage | Frozen Embryo Transfer | Hormone Replacement Therapy | Letrozole | Live Birth | Polycystic Ovarian Disease
MedSIR
GlaxoSmithKline

Completed

Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) (LUZERN)

Breast Cancer | Breast Cancer Metastatic

Spain
Sun Yat-sen University

Active, not recruiting

Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer (MECCA)

Breast Cancer

China
MedSIR

Active, not recruiting

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (PHERGain)

Breast Cancer

Spain, Italy, France, United Kingdom, Germany, Portugal, Belgium
IVI Madrid

Active, not recruiting

Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors. (LETRODON)

Luteinised Follicular Cyst

Spain
Rigshospitalet, Denmark

Terminated

A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial

Hypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, Male

Denmark
Duke University

Active, not recruiting

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Metastatic Breast Cancer | Locally Advanced Breast Cancer | Hormone Receptor Positive Tumor

United States
Centre Leon Berard

Active, not recruiting

Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) (VICTORIA)

Endometrial Carcinoma | Hormone Receptor Positive Tumor | Metastatic Carcinoma

France
Ente Ospedaliero Ospedali Galliera
Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Istituto Di Ricerche... and other collaborators

Terminated

Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer (EXPERT)

Ovarian Cancer

Italy
AstraZeneca

Active, not recruiting

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (FALCON)

Hormone Receptor Positive Breast Cancer

Canada, Spain, United States, Romania, Taiwan, Italy, Brazil, Peru, Russian Federation, China, Czechia, Ukraine, South Africa, Japan, Poland, Mexico, United Kingdom, Argentina, Slovakia, Turkey
Capital Medical University

Completed

Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients

Breast Neoplasms | Neoplasm Metastasis

China
University of Michigan Rogel Cancer Center
Damon Runyon Cancer Research Foundation

Completed

Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients

Pain | Breast Cancer | Arthralgia

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Pfizer

Active, not recruiting

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

Metastatic Breast Cancer

United States
Alliance Foundation Trials, LLC.
Pfizer; Syneos Health; UNICANCER; German Breast Group; SOLTI Breast Cancer Research... and other collaborators

Active, not recruiting

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)

HER-2 Positive Breast Cancer | Estrogen Receptor Positive Breast Cancer

United States, Spain, France, Italy, Germany, Australia, Portugal, New Zealand
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease

Breast Cancer | Joint Pain

United States
Cambridge University Hospitals NHS Foundation Trust
Anticancer Fund, Belgium

Completed

A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer (PIONEER)

Breast Cancer

United Kingdom
AstraZeneca
Daiichi Sankyo Co., Ltd.; Daiichi Sankyo Company, Limited

Active, not recruiting

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (DB-08)

Metastatic Breast Cancer

Belgium, United States, Taiwan, Korea, Republic of, Brazil, Russian Federation, Canada, Australia, France, Mexico
Veru Inc.

Terminated

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer (ARTEST)

Metastatic Breast Cancer

United States, Spain, Poland, Ukraine
Providence Health & Services

Active, not recruiting

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Breast Cancer

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
Novartis Pharmaceuticals

Completed

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (BOLERO-5)

Advanced Breast Cancer

China
Beth Israel Deaconess Medical Center
National Institute on Alcohol Abuse and Alcoholism (NIAAA); Dana-Farber Cancer...

Completed

Alcohol and Breast Cancer (ABC) Trial

Breast Cancer | Aromatase Inhibitors | ER+ Breast Cancer

United States
Shayna Showalter, MD

Active, not recruiting

Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer (POWER)

Breast Cancer Female

United States
GOG Foundation
Novartis Pharmaceuticals

Active, not recruiting

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

Advanced, Persistent, or Recurrent Endometrial Cancer

United States
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); Breast International Group

Active, not recruiting

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (TEXT)

Breast Cancer

United States, Australia, Switzerland, Italy, Canada, Belgium, Peru, United Kingdom, Egypt, New Zealand, Slovenia, South Africa, Sweden, Hungary, India, Germany, Brazil
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia... and other collaborators

Active, not recruiting

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (SOFT)

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States, Canada, Switzerland
Mayo Clinic
National Cancer Institute (NCI)

Completed

Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

Breast Cancer

United States
University of Alabama at Birmingham
Novartis Pharmaceuticals; Tracon Pharmaceuticals Inc.

Completed

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Atypical Hyperplasia

United States
Georgetown University
Pfizer

Active, not recruiting

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Metastatic Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone Receptor Positive Breast Cancer

United States
Washington University School of Medicine
Pfizer

Active, not recruiting

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Breast Neoplasms

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

Breast Cancer

United States, Puerto Rico
Canadian Cancer Trials Group
Pfizer

Completed

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Breast Cancer

Canada
Pfizer

Completed

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

Breast Cancer | Breast Neoplasms | Breast Tumors | Breast Carcinoma | Cancer of Breast

India
MedSIR
Cellestia Biotech AG

Terminated

CB-103 Plus NSAI In Luminal Advanced Breast Cancer (CAILA)

Advanced Breast Cancer

Spain
Vanderbilt-Ingram Cancer Center

Active, not recruiting

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

Estrogen Receptor-positive Breast Cancer

United States
Gynecologic Oncology Group
Eli Lilly and Company

Active, not recruiting

Abemaciclib and Letrozole to Treat Endometrial Cancer

Endometrial Cancer

United States
Sanofi

Terminated

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (AMEERA-5)

Breast Cancer

United States, Russian Federation, Italy, Australia, Belgium, France, Japan, Ukraine, Netherlands, Argentina, Canada, Portugal, Spain, Austria, Brazil, Bulgaria, Chile, China, Czechia, Finland, Georgia, Germany, Hungary, Korea, Republic... and more

Search clinical trials for: Aromatase Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations